The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the Egrifta SV label, and added the Drugs@FDA approval record. 12
What this version reported
Two randomized, placebo-controlled trials described in the label found larger reductions in visceral abdominal fat than placebo. The label states that it is not indicated for weight loss and that long-term cardiovascular safety has not been established.↗
Reader guide in this version
Key takeaway
Tesamorelin is a lab-made version of growth hormone-releasing factor, the brain hormone that prompts the pituitary gland to release growth hormone.1 It is FDA-approved as Egrifta for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. Drugs@FDA lists its original approval on November 10, 2010.1,2 The label states that it is not indicated for weight loss and that its long-term cardiovascular safety has not been established.1 The approval rests on two randomized, placebo-controlled trials of about 400 adults each, in which visceral abdominal fat fell more with tesamorelin than with placebo.1
At a glance
- What it is
- A growth hormone-releasing factor (GHRF) analogue. The label states that it binds to and stimulates human GRF receptors with potency similar to the natural hormone.1
- FDA status
- FDA-approved. Drugs@FDA lists Egrifta (first approved November 10, 2010), and the label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. The cited label has no boxed warning.1,2
- Human evidence
- Two large randomized, double-blind, placebo-controlled trials described in the label, each with a 26-week main phase and a 26-week extension.1
- Evidence strength
- Large randomized human trials
What is tesamorelin?
Tesamorelin is a lab-made analogue of growth hormone-releasing factor (GHRF), also called growth hormone-releasing hormone (GHRH). The label describes GHRF as a hypothalamic peptide that acts on the pituitary gland to stimulate the release of the body’s own growth hormone.1
In the United States it is the active ingredient of Egrifta, from Theratechnologies, according to Drugs@FDA.2
How does tesamorelin work?
The label states that tesamorelin binds to and stimulates human GRF receptors with potency similar to the natural hormone, prompting the pituitary to make and release growth hormone.1
According to the label, growth hormone has both tissue-building and fat-breaking effects, some of which are carried by IGF-1, a growth factor made in the liver and other tissues.1
The label states that tesamorelin increases IGF-1 levels and that the effects of prolonged IGF-1 elevation are unknown.1
What do human studies show?
The label describes two randomized, double-blind, placebo-controlled trials in adults with HIV, lipodystrophy and excess abdominal fat who were on stable HIV treatment: Study 1 with 412 participants and Study 2 with 404.1
At 26 weeks, visceral abdominal fat measured by CT scan fell by an average of 18% with tesamorelin and rose 2% with placebo in Study 1, and fell 14% with tesamorelin and 2% with placebo in Study 2, according to the label.1
Body weight barely changed in either group, consistent with the label’s statement that the drug is not indicated for weight loss because it has a weight-neutral effect.1
The label reports 26-week completion rates of 80% in Study 1 and 74% in Study 2. The trials excluded people with a history of cancer, an underactive pituitary gland, or previous treatment with insulin or other diabetes medicines.1
What the evidence base contains
- Large randomized human trial Study 1 (NCT00123253): a randomized, double-blind, placebo-controlled trial in 412 adults with HIV, lipodystrophy and excess abdominal fat, with visceral fat measured by CT scan at 26 weeks.1
- Large randomized human trial Study 2 (NCT00435136): a randomized, double-blind, placebo-controlled trial of the same design in 404 adults.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Is tesamorelin FDA-approved?
Yes. Drugs@FDA lists Egrifta, application BLA022505, with an original approval date of November 10, 2010.2
The Egrifta SV label cited here (DailyMed SPL version 9, published July 31, 2026) states that it is indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.1
The label lists these limitations of use: long-term cardiovascular safety has not been established, it is not indicated for weight loss, and there are no data showing that it improves adherence to HIV treatment.1
The label has no boxed warning. It states that tesamorelin is contraindicated in pregnancy, in people with active cancer, with disruption of the hypothalamic-pituitary axis, or with known allergy to it.1
Its warnings cover an increased risk of tumors, elevated IGF-1, fluid retention, glucose intolerance or diabetes, allergic reactions and increased deaths in people with acute critical illness.1
What is still unknown?
Its long-term cardiovascular safety, which the label says has not been established.1
The effects of keeping IGF-1 levels raised for long periods, which the label says are unknown.1
Whether the reduction in abdominal fat leads to longer-term health benefits: the label’s trials measured fat by CT scan over 26-week phases.1
Its effects outside the approved population: the label’s trials enrolled adults with HIV and lipodystrophy only.1
Sources for this version
- 1EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 2Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026